NCT00932698View on ClinicalTrials.gov

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 12, 2009

Primary Completion Date

June 20, 2013

Study Completion Date

May 23, 2017

Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
DRUG

Ixazomib

Ixazomib capsules

Trial Locations (5)

30322

Emory University, Atlanta

33617

H. Lee Moffitt Cancer Center, Tampa

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

77030

M.D. Anderson Cancer Center, Houston

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00932698 - Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | Biotech Hunter | Biotech Hunter